Expansion will help drive new levels of efficiency and agility
globally
PLEASANTON, Calif.--(BUSINESS WIRE)--
Veeva
Systems (NYSE:VEEV) today announced that Merck (NYSE:MRK), known as
MSD outside of the United States and Canada, is expanding its use of
multichannel Veeva
CRM to additional markets, including Latin America and Asia Pacific.
Veeva and Merck are building upon their seven-year partnership to help
Merck standardize on a single global CRM solution in order to drive new
levels of operating efficiency and commercial effectiveness worldwide.
“Our ability to consistently deliver world-class cloud software helps
keep our customers ahead as the life sciences industry evolves,” said
Peter Gassner, founder and CEO at Veeva. “We are proud to team with
Merck on their important mission to bring innovative medicines to
market.”
“Veeva has been a trusted, long-term partner of Merck’s,”
said Phyllis Post, vice president and CIO for Global Human Health at
Merck. “Moving to a single global CRM solution can help us be more agile
while providing the foundation for delivering an efficient and
personalized customer experience.”
As part of its expansion with Veeva, Merck will now utilize Veeva CRM, Veeva
CRM Approved Email, and Veeva
CRM Events Management for all users and markets around the globe to
enable a seamless customer experience across channels.
Join Veeva at the upcoming 2018
Veeva Commercial & Medical Summit, May 14-16, 2018, in
Philadelphia. Registration for the event is complimentary for Veeva
customers and invited guests. Register and view the agenda at veeva.com/Summit.
Additional Information
For more on Veeva CRM, visit: veeva.com/CRM
Connect
with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow
@veevasystems on Twitter: twitter.com/veevasystems
Like
Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 600 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the results
from use of Veeva’s products and services and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva’s historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva’s expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva’s financial results are included under the captions,
“Risk Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on Form
10-K for the period ended January 31, 2018. This is available on the
company’s website at veeva.com
under the Investors section and on the SEC’s website at sec.gov.
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to
time.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180507005457/en/
Source: Veeva Systems Inc.